MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $10.43 (365.56% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2016Brean CapitalReiterated RatingBuy$13.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Roth CapitalReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2015JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Stifel NicolausLower Price TargetBuy$11.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015Piper JaffrayReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2015HC WainwrightInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015MLV & Co.Set Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/24/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha